ROYALTY PURCHASE AGREEMENT BY AND BETWEEN APR APPLIED PHARMA RESEARCH S.A. AND SWK FUNDING LLC DATED AS OF DECEMBER 2, 2015Royalty Purchase Agreement • July 11th, 2022 • Relief Therapeutics Holding SA • Pharmaceutical preparations • New York
THIS ROYALTY PURCHASE AGREEMENT entered and made effective as of this 2nd day of December, 2015 (this “Agreement”), by and between APR APPLIED PHARMA RESEARCH S.A., a corporation organized and existing according to the laws of Switzerland (“Seller”), and SWK FUNDING LLC, a Delaware limited liability company (“Purchaser”).
Royalty Purchase AgreementRoyalty Purchase Agreement • August 25th, 2006 • International Royalty Corp • British Columbia
Each of the Vendors wishes to sell, and the Purchaser wishes to purchase, the Royalties on the terms and conditions set forth in this Agreement; and
ROYALTY PURCHASE AGREEMENT dated as of January 6, 2018 between ANTIGENICS LLC, as Seller and HEALTHCARE ROYALTY PARTNERS III, L.P., AND CERTAIN AFFILIATED FUNDS IDENTIFIED HEREIN, collectively as PurchaserRoyalty Purchase Agreement • July 29th, 2021 • Healthcare Royalty, Inc. • Pharmaceutical preparations • New York
ROYALTY PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of January 6, 2018, by and between ANTIGENICS LLC, a Delaware limited liability company (the “Seller”) and the entities set forth on Schedule 1 in the proportions set forth thereon (collectively, the “Purchaser”).
ROYALTY PURCHASE AGREEMENT BETWEEN NEUROSCIENCE PARTNERS LIMITED PARTNERSHIP BY ITS GENERAL PARTNER, MDS ASSOCIES-NEUROSCIENCE INC. - AND - APOLLO GENETICS, INC. DECEMBER 18, 1996Royalty Purchase Agreement • March 17th, 1997 • Apollo Biopharmaceutics Inc • Pharmaceutical preparations • Massachusetts
CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ROYALTY PURCHASE AGREEMENT (MONJUVI®/MINJUVI®) XENCOR,...Royalty Purchase Agreement • November 7th, 2023 • Xencor Inc • Pharmaceutical preparations • New York
ContractRoyalty Purchase Agreement • November 7th, 2018 • Agenus Inc • Biological products, (no disgnostic substances) • New York
[********] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Royalty Purchase Agreement By and Between PureTech Health LLC, as the Seller, and Solely for purposes of Article 4 and Section 10.13, PureTech Health PLC, as the Seller Parent, on the one hand and Royalty Pharma Investments 2019 ICAV, as the Buyer, on...Royalty Purchase Agreement • April 28th, 2023 • PureTech Health PLC • Pharmaceutical preparations • New York
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDED AND RESTATED...Royalty Purchase Agreement • February 29th, 2024 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED ROYALTY PURCHASE AGREEMENT, dated as of October 18, 2023 (this “Agreement”), is made and entered into by and among PTC Therapeutics, Inc., a Delaware corporation (the “Seller”), Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Buyer”), and, solely for the purposes of Section 5.15 hereof, Royalty Pharma plc, a limited company organized under the laws of England and Wales.
ROYALTY PURCHASE AGREEMENT BETWEEN Dorato Resources Inc. - and - Franco-Nevada Corporation June 22, 2012Royalty Purchase Agreement • June 3rd, 2013 • Dorato Resources Inc • Services-business services, nec • Ontario
THIS ROYALTY PURCHASE AGREEMENT is dated as of the 22nd day of June, 2012, by and between Dorato Resources Inc., a corporation organized under the laws of British Columbia, whose address for purposes hereof is Suite 2300 – 1177 West Hastings Street, Vancouver, British Columbia V6E 2K3 (“Dorato”) and Franco-Nevada Corporation, a corporation organized under the laws of Canada, whose address for purposes hereof is Exchange Tower, 130 King Street West, Suite 740, PO Box 467, Toronto, Ontario M5X 1E4 (“Franco”).
ROYALTY PURCHASE AGREEMENT dated as of March 22, 2021 between VIRACTA THERAPEUTICS, INC., as Seller, and XOMA (US) LLC, as PurchaserRoyalty Purchase Agreement • May 13th, 2021 • Viracta Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This ROYALTY PURCHASE AGREEMENT (this “Agreement”) dated as of March 22, 2021 (the “Effective Date”), is between VIRACTA THERAPEUTICS, INC., a corporation organized and existing under the laws of Delaware, with an office located at 2533 South Coast Highway 101, #210, Cardiff CA 92007 (“Seller”), and XOMA (US) LLC, a Delaware limited liability company with its principal place of business at 2200 Powell Street, Suite 310, Emeryville, California 94608 (“Purchaser”).
Royalty Purchase AgreementRoyalty Purchase Agreement • February 19th, 2021 • Longboard Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Royalty Purchase Agreement (the “Agreement”), dated as of October 27, 2020, is by and between Arena Pharmaceuticals, Inc. (“Parent”), 356 Royalty Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“356”), and Longboard Pharmaceuticals, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (the “Company”). Capitalized terms used but not defined herein shall have the meaning ascribed to such terms in that certain Transaction Agreement, dated as of December 28, 2016, by and among 356, Eisai Inc. and Eisai Co., Ltd. (the “Transaction Agreement”).
ROYALTY PURCHASE AGREEMENTRoyalty Purchase Agreement • May 26th, 2015 • Medical Imaging Corp. • Services-medical laboratories
WHEREAS the Purchaser wishes to acquire from the Corporation, and the Corporation wishes to sell to the Purchaser, a gross sales royalty on the terms and conditions contained herein.
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL ANDRoyalty Purchase Agreement • March 3rd, 2022 • Concert Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Royalty Purchase Agreement is dated as of November 3, 2021 (this “Agreement”), by and among Concert Pharmaceuticals, Inc., a Delaware corporation (the “Seller”), each buyer identified on the signature pages hereto (each, including its successors and assigns, a “Buyer” and collectively the “Buyers” and including the RA Buyer Representative in its capacity as such) and the BVF Buyer Representative (as defined below).
ROYALTY PURCHASE AGREEMENT dated as of December 17, 2020 between EYEPOINT PHARMACEUTICALS, INC. EYEPOINT PHARMACEUTICALS US, INC. and SWK FUNDING LLCRoyalty Purchase Agreement • March 12th, 2021 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • New York
ContractRoyalty Purchase Agreement • May 2nd, 2023 • Atlas Lithium Corp • Mining & quarrying of nonmetallic minerals (no fuels) • Ontario
Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential, and such information has been marked at the appropriate place with [***].
ROYALTY PURCHASE AGREEMENT Agreement made as of March 18, 2005 BetweenRoyalty Purchase Agreement • August 25th, 2006 • International Royalty Corp • British Columbia
BHP Billiton World Exploration Inc., BHP Billiton Diamonds Inc., BHP Billiton Minerals Pty Ltd., BHP Minerals International Exploration Inc., BHP Minerals Ghana Inc., BHP Holdings (International) Inc., BHP Brasil Ltda., Minera BHP Billiton, S.A. De C.V. and BHP Minerals Holdings Proprietary Limited
ROYALTY PURCHASE AGREEMENT BY AND BETWEEN CYTOKINETICS, INCORPORATED AND RPI FINANCE TRUST DATED AS OF FEBRUARY 1, 2017Royalty Purchase Agreement • March 6th, 2017 • Cytokinetics Inc • Pharmaceutical preparations • New York
This ROYALTY PURCHASE AGREEMENT, dated as of February 1, 2017 (this “Agreement”), is made and entered into by and between Cytokinetics, Incorporated, a Delaware corporation (the “Seller”), on the one hand, and RPI Finance Trust, a Delaware statutory trust (the “Buyer”), on the other hand.
AMENDMENT NO. 1 TO ROYALTY PURCHASE AGREEMENTRoyalty Purchase Agreement • March 7th, 2024 • Viracta Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 to Royalty Purchase Agreement (this “Amendment”) is entered into as of March 4, 2024 (the “Amendment Effective Date”) by and between VIRACTA THERAPEUTICS, INC., a corporation organized and existing under the laws of Delaware, with an office located at 2533 South Coast Highway 101, #210, Cardiff CA 92007 (“Viracta”), VIRACTA ROYALTY FUND, LLC, a Delaware limited liability company (collectively, with Viracta, “Seller”), and XOMA (US) LLC, a Delaware limited liability company with its principal place of business at 2200 Powell Street, Suite 310, Emeryville, California 94608 (“Purchaser”). Seller and Purchaser are referred to in this Amendment individually as a “Party” and collectively as the “Parties”. Capitalized terms used herein and not otherwise defined shall have the respective meanings given to such terms in the Royalty Purchase Agreement (defined below).
ROYALTY PURCHASE AGREEMENTRoyalty Purchase Agreement • November 13th, 2012 • Arrayit Diagnostics, Inc. • Texas
THIS AGREEMENT is made and entered into this first day of March, 2012 by and between Recap Marketing and Consulting, LLP, 12000 Westheimer Suite 340, Houston, Texas 77077, (“Seller”) and Arrayit Diagnostics, Inc. Nevada corporation (“Purchaser”).
ROYALTY PURCHASE AGREEMENT QUESTCAP INC.Royalty Purchase Agreement • January 8th, 2020 • Ontario
AND WHEREAS the Purchaser has agreed to purchase, and the Vendor has agreed to sell, the Royalty in consideration for the aggregate purchase price of $10,000,000 (the “Purchaser Price”), to be paid by the Purchaser to the Vendor pursuant to and in accordance with the terms of this Agreement;
AMENDMENT NO. 1 TO ROYALTY Purchase AGREEMENTRoyalty Purchase Agreement • August 9th, 2021 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This Amendment No. 1 to Royalty Purchase Agreement (this “Amendment”) is made and entered into as of June 22, 2021 by and among Antigenics LLC, a Delaware limited liability company (the “Seller”) and the entities set forth on Schedule 1 to the (as defined below) Agreement in the proportions set forth thereon (collectively, the “Buyer”). Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Agreement (as defined below).
Royalty Purchase Agreement Between REGENXBIO Inc., as Seller the entities set forth on Schedule 1.1 HERETO, as Purchaser, and HCR COLLATERAL MANAGEMENT LLC, as Purchaser Representative Dated as of December 22, 2020Royalty Purchase Agreement • March 1st, 2021 • REGENXBIO Inc. • Biological products, (no disgnostic substances) • New York
Royalty Purchase Agreement, dated as of December 22, 2020 (this “Agreement”), between REGENXBIO Inc., a Delaware corporation, as Seller (“Seller”), the entities set forth on Schedule 1.1, as Purchaser (collectively, “Purchaser”), and, solely in its capacity as representative of the Purchaser, HCR COLLATERAL MANAGEMENT LLC, a Delaware limited liability company (“HCR Agent”).
Royalty Purchase Agreement By and Between Ultragenyx Pharmaceutical Inc. and RPI Finance Trust Dated as of December 17, 2019Royalty Purchase Agreement • February 14th, 2020 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This ROYALTY PURCHASE AGREEMENT, dated as of December 17, 2019 (this “Agreement”), is made and entered into by and between Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Seller”), on the one hand, and RPI Finance Trust, a Delaware statutory trust (the “Buyer”), on the other hand.
Royalty Purchase Agreement By and Between Minerva Neurosciences, Inc. and RPI 2019 Intermediate Finance Trust Dated as of January 15, 2021Royalty Purchase Agreement • March 8th, 2021 • Minerva Neurosciences, Inc. • Pharmaceutical preparations • New York
This ROYALTY PURCHASE AGREEMENT, dated as of January 15, 2021 (this “Agreement”), is made and entered into by and between Minerva Neurosciences, Inc., a Delaware corporation (the “Seller”), on the one hand, and RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (the “Buyer”), on the other hand.
Royalty Purchase AgreementRoyalty Purchase Agreement • August 25th, 2006 • International Royalty Corp • British Columbia
The Vendor wishes to sell, and the Purchaser wishes to purchase, the Royalty on the terms and conditions set forth in this Agreement.
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN OMITTED. ROYALTY PURCHASE AGREEMENT...Royalty Purchase Agreement • April 27th, 2023 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations • New York
ROYALTY PURCHASE AGREEMENT, dated as of April 25, 2023 (this “Agreement”), between ENANTA PHARMACEUTICALS, INC., a Delaware corporation, as Seller (“Seller”), and OCM LIFE SCIENCES PORTFOLIO LP, an Ontario limited partnership, as Purchaser (“Purchaser”).
ROYALTY PURCHASE AGREEMENT July 29, 2021Royalty Purchase Agreement • March 30th, 2022 • EMX Royalty Corp • Metal mining • British Columbia
Royalty Purchase Agreement dated July 29, 2021 between EMX Royalty Corporation (the "Purchaser") and SSR Mining Inc. ("SSR") and the subsidiaries of SSR listed as "Vendors" on the signature pages hereto (collectively with SSR, the "Vendors").
ROYALTY PURCHASE AGREEMENTRoyalty Purchase Agreement • November 17th, 2011 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This ROYALTY PURCHASE AGREEMENT (this “Agreement”), dated November 14, 2011, is made by and between Deerfield Private Design Fund II, L.P., a Delaware limited partnership (“Design Fund II”), Deerfield Special Situations Fund, L.P., a Delaware limited partnership (“DSS”), Horizon Santé TTNP SARL, a Luxembourg limited company (“Horizon” and together with Design Fund II and DSS, “Deerfield”) and Titan Pharmaceuticals, Inc., a Delaware corporation (“Titan”).
ContractRoyalty Purchase Agreement • January 12th, 2021 • Gold Royalty Corp. • Gold and silver ores • British Columbia
[*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
URANIUM ENERGY CORP. -AND- URANIUM ROYALTY CORP. ROYALTY PURCHASE AGREEMENT August 20, 2018Royalty Purchase Agreement • October 15th, 2018 • Uranium Energy Corp • Miscellaneous metal ores • British Columbia
uranium energy corp., a corporation existing under the laws of Nevada and having an address at 500 North Shoreline, Suite 800N, Corpus Christi, Texas 78401
Royalty PURCHASE Agreement (Palmetto Royalty; Esmeralda County, Nevada)Royalty Purchase Agreement • February 1st, 2022 • Nevada Canyon Gold Corp. • Gold and silver ores • Nevada
Royalty Percentage. For good and valuable consideration, the receipt and sufficiency of which are acknowledged by the Parties, Obligor grants, sells, assigns and conveys to Royalty Holder, and its successors and assigns forever, a production royalty in an amount equal to two percent (2%) of the Net Smelter Returns (the “Royalty Percentage”), as hereinafter defined and computed, for all gold and other minerals of any type produced from the Properties, including all gold and other minerals of any type produced from dumps or stockpiles located on the Properties, from and after the Effective Date (the “Royalty”), subject to Section 1(b).
AMENDMENT TO ROYALTY PURCHASE AGREEMENTRoyalty Purchase Agreement • August 11th, 2022 • Aptevo Therapeutics Inc. • Pharmaceutical preparations
This Amendment, dated as of June 7, 2022 (this “Amendment”), to the Royalty Purchase Agreement, dated as of March 30, 2021 (the “Purchase Agreement”), is made and entered into by and among Aptevo Therapeutics Inc., a Delaware corporation (“Seller”) and Healthcare Royalty Partners IV, L.P., a Delaware limited partnership (“Buyer”). Buyer and Seller are each individually referred to herein as a “Party” and, collectively, as the “Parties”. Capitalized terms used but not defined herein (including capitalized terms used in the preamble and recitals hereto) shall have the meanings ascribed to such terms in the Purchase Agreement.
Royalty Purchase Agreement By and Between Cytokinetics, Incorporated and Dolya Holdco 19 Designated Activity CompanyRoyalty Purchase Agreement • November 6th, 2020 • Cytokinetics Inc • Pharmaceutical preparations • New York
This Royalty Purchase Agreement, dated as of July 14, 2020 (this “Agreement”), is made and entered into by and between Cytokinetics, Incorporated, a Delaware corporation (the “Seller”), on the one hand, and Dolya Holdco 19 Designated Activity Company (in the process of changing its name to RTW Royalty Holdings Designated Activity Company), a designated activity company incorporated under the laws of Ireland under company number 669527 and whose registered office is at [*] (the “Buyer”), on the other hand.
Royalty Purchase Agreement By and Between MorphoSys AG and Royalty Pharma Investments 2019 ICAV Dated as of June 2, 2021Royalty Purchase Agreement • March 16th, 2022 • MorphoSys AG • Pharmaceutical preparations • New York
Royalty Purchase Agreement By and Between Rare Delaware Inc. Ultragenyx Pharmaceutical Inc. and OCM LS23 Holdings LP Dated as of July 14, 2022Royalty Purchase Agreement • July 29th, 2022 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This Royalty Purchase Agreement (this “Agreement”), dated as of July 14, 2022 (the “Effective Date”), is made and entered into by and among Rare Delaware Inc., a Delaware corporation (“Seller”), Ultragenyx Pharmaceutical Inc., a Delaware corporation and the direct parent of Seller (“Ultragenyx”) and OCM LS23 Holdings LP, an Ontario limited partnership (“Buyer”).
